Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific...

Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at
Scientific Conferences

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
("Rib-X" or the "Company"), a development-stage company focused on the
discovery and development of novel antibiotics for the treatment of
antibiotic-resistant infections, announced today that company representatives
are giving three presentations at two conferences this week.
Gordon Research Conference on Medicinal Chemistry, August 3-8
Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon
Research Conference on Medicinal Chemistry this week at Colby Sawyer College,
New London, NH. Dr. Bhattacharjee introduced Rib-X's enhanced macrolide
program in a poster session titled, "Structure-Based Drug Design Targeting
Infectious Disease: Overcoming Resistance and Extending the Antimicrobial
Spectrum of Macrolide Antibiotics." In his presentation on August 3 and 4,
Dr. Bhattacharjee highlighted how the combination of structural insights from
X-ray crystallographic studies of known and new antibiotics bound to the
bacterial 50S ribosomal subunit with data-driven computational chemistry tools
allows for a fresh look at macrolide antibiotics.
Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will
give a presentation in the "Late-Breaking Topics" session, Thursday, August 7.
The title of the talk is "Discovery and Clinical Development of radezolid
(RX-1741), a Designer Oxazolidinone" and will highlight the company's
proprietary discovery process utilizing structural, computational and
chemistry approaches; radezolid has distinct physical properties as well as a
promising efficacy and safety profile.
Drug Discovery & Development of Innovative Therapeutics World Conference,
August 4-7
Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X
Pharmaceuticals, Inc., is presenting Rib-X's RX-04 program at IBC's 12th
Annual Drug Discovery & Development of Innovative Therapeutics World
Conference Technology Conference today at 11:00 AM ET at The World Trade
Center Boston and Seaport Hotel, Boston, MA. Dr. DeVito will highlight RX-04
in a presentation titled "Using Structure-Based Discovery to Define Novel
Antibiotics Targeting the 50S Ribosomal Subunit." RX-04 is Rib-X's de novo
design of three completely new series of antibacterials showing promising
activity against serious multidrug resistant Gram-negative pathogens,
including, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella
pneumoniae, Acinetobacter baumanii and Escherichia coli.
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug
discovery and development company focused on the structure-based design of new
classes of antibiotics. The Company's underlying drug discovery engine
capitalizes on its proprietary high-resolution crystal structure of the
ribosome, which performs an essential role in the fundamental process of
protein synthesis. Many known, commercially valuable antibiotics bind to the
ribosome, including those used to treat both community-acquired and
hospital-acquired pathogens. The Company's integrated research strategy, which
combines state of the art, proprietary computational analysis, X-ray
crystallography, medicinal chemistry, microbiology and biochemistry, allows it
to rapidly synthesize new agents designed to avoid typical antibiotic
resistance mechanisms. Rib-X's iterative intelligent engine has yielded
several distinctive new antibiotic classes. The Company currently has two
programs in human clinical trials, the radezolid (RX-1741) designer
oxazolidinone program as an oral/IV agent to treat serious hospital
Gram-positive infections and the delafloxacin, (RX-3341) program, a next
generation fluoroquinolone, active against a broad spectrum of bacteria,
including methicillin-resistant Staphylococcus aureus. Additionally, the
Company has multiple drug discovery programs. The first of these is a rapidly
developing discovery program that has identified a new chemical classes of
antibiotics active against multi-drug resistant Gram negative bacteria in the
hospital. The second of these programs is focused on design and development of
an IV and orally active macrolide for treatment of infections in the nursing
home and hospital setting, including those caused by MRSA and enterococci.
For more information on the ribosome and the Rib-X mission, please visit
the Company website at www.rib-x.com.
SOURCE Rib-X Pharmaceuticals, Inc.

Investors: John Capodanno, +1-212-850-5705, matthew.duch@fd.com, or Media:
Irma Gomez-Dib, +1-212-850-5761, irma.gomez-dib@fd.com, both of FD Life
Sciences